Published in Trop Med Int Health on February 17, 2010
Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health (2010) 8.81
Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS (2010) 4.68
Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol (2011) 3.33
Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med (2011) 2.80
Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med (2013) 2.60
Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa. Int J Epidemiol (2012) 2.19
Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS One (2011) 2.11
Better antiretroviral therapy outcomes at primary healthcare facilities: an evaluation of three tiers of ART services in four South African provinces. PLoS One (2010) 1.86
Adjusting mortality for loss to follow-up: analysis of five ART programmes in sub-Saharan Africa. PLoS One (2010) 1.84
Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health care clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr (2013) 1.77
Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa. AIDS Res Hum Retroviruses (2013) 1.67
Methodological and policy limitations of quantifying the saving of lives: a case study of the Global Fund's approach. PLoS Med (2013) 1.65
Outcomes of antiretroviral treatment programs in rural Southern Africa. J Acquir Immune Defic Syndr (2012) 1.60
Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy. Sex Transm Infect (2010) 1.59
Loss to follow-up before and after delivery among women testing HIV positive during pregnancy in Johannesburg, South Africa. Trop Med Int Health (2013) 1.58
Outcomes and associated risk factors of patients traced after being lost to follow-up from antiretroviral treatment in Lilongwe, Malawi. BMC Infect Dis (2011) 1.47
The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc (2010) 1.45
Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. PLoS One (2013) 1.29
Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS (2011) 1.28
Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr (2011) 1.22
Association of adherence support and outreach services with total attrition, loss to follow-up, and death among ART patients in sub-Saharan Africa. PLoS One (2012) 1.19
Mortality associated with delays between clinic entry and ART initiation in resource-limited settings: results of a transition-state model. J Acquir Immune Defic Syndr (2013) 1.18
Cost of using a patient tracer to reduce loss to follow-up and ascertain patient status in a large antiretroviral therapy program in Johannesburg, South Africa. Trop Med Int Health (2010) 1.18
Long-term costs and health impact of continued global fund support for antiretroviral therapy. PLoS One (2011) 1.16
Kaposi's Sarcoma in HIV-infected patients in South Africa: Multicohort study in the antiretroviral therapy era. Int J Cancer (2014) 1.16
Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients. J Womens Health (Larchmt) (2013) 1.14
Treatment outcomes after 7 years of public-sector HIV treatment. AIDS (2012) 1.11
Impact of definitions of loss to follow-up on estimates of retention, disease progression, and mortality: application to an HIV program in Mozambique. Am J Epidemiol (2013) 1.11
Monitoring of antiretroviral therapy and mortality in HIV programmes in Malawi, South Africa and Zambia: mathematical modelling study. PLoS One (2013) 1.11
The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc (2011) 1.11
Poorer ART outcomes with increasing age at a large public sector HIV clinic in Johannesburg, South Africa. J Int Assoc Physicians AIDS Care (Chic) (2011) 1.10
Long-term antiretroviral treatment outcomes in seven countries in the Caribbean. J Acquir Immune Defic Syndr (2012) 1.09
Non-ignorable loss to follow-up: correcting mortality estimates based on additional outcome ascertainment. Stat Med (2013) 1.09
Incident pregnancy and time to death or AIDS among HIV-positive women receiving antiretroviral therapy. PLoS One (2013) 1.05
Impact of definitions of loss to follow-up (LTFU) in antiretroviral therapy program evaluation: variation in the definition can have an appreciable impact on estimated proportions of LTFU. J Clin Epidemiol (2013) 1.04
Prevalent pregnancy, biological sex, and virologic response to antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 1.03
Predictive value of anemia for tuberculosis in HIV-infected patients in Sub-Saharan Africa: an indication for routine microbiological investigation using new rapid assays. J Acquir Immune Defic Syndr (2014) 0.99
A comparison of death recording by health centres and civil registration in South Africans receiving antiretroviral treatment. J Int AIDS Soc (2015) 0.99
Comparison of methods to correct survival estimates and survival regression analysis on a large HIV African cohort. PLoS One (2012) 0.95
Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study. PLoS One (2013) 0.94
Loss to clinic and five-year mortality among HIV-infected antiretroviral therapy initiators. PLoS One (2014) 0.94
Return to normal life after AIDS as a reason for lost to follow-up in a community-based antiretroviral treatment program. J Acquir Immune Defic Syndr (2012) 0.93
The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa. PLoS One (2013) 0.91
Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. J Int AIDS Soc (2014) 0.89
CD4-specific mortality rates among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa. J Acquir Immune Defic Syndr (2012) 0.89
Prevalent tuberculosis and mortality among HAART initiators. AIDS (2012) 0.87
The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting. Trop Med Int Health (2013) 0.86
Increased risk of mortality and loss to follow-up among HIV-positive patients with oropharyngeal candidiasis and malnutrition before antiretroviral therapy initiation: a retrospective analysis from a large urban cohort in Johannesburg, South Africa. Oral Surg Oral Med Oral Pathol Oral Radiol (2012) 0.84
CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa. J Acquir Immune Defic Syndr (2013) 0.84
The predictive value of current haemoglobin levels for incident tuberculosis and/or mortality during long-term antiretroviral therapy in South Africa: a cohort study. BMC Med (2015) 0.83
A novel approach to accounting for loss to follow-up when estimating the relationship between CD4 Count at ART initiation and mortality. PLoS One (2013) 0.83
Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa. Int J Infect Dis (2014) 0.83
Kaposi sarcoma-associated herpes virus and response to antiretroviral therapy: a prospective study of HIV-infected adults. J Acquir Immune Defic Syndr (2013) 0.82
CD4+ gain percentile curves for monitoring response to antiretroviral therapy in HIV-infected adults. AIDS (2015) 0.80
The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. J Int AIDS Soc (2014) 0.80
HIV-Related Medical Admissions to a South African District Hospital Remain Frequent Despite Effective Antiretroviral Therapy Scale-Up. Medicine (Baltimore) (2015) 0.79
Incidence and predictors of attrition from antiretroviral care among adults in a rural HIV clinic in Coastal Kenya: a retrospective cohort study. BMC Public Health (2015) 0.78
Antiretroviral therapy initiation during tuberculosis treatment and HIV-RNA and CD4 T-lymphocyte responses. Int J Tuberc Lung Dis (2012) 0.77
Impact of three empirical anti-tuberculosis treatment strategies for people initiating antiretroviral therapy. Int J Tuberc Lung Dis (2014) 0.77
Can Short-Term Use of Electronic Patient Adherence Monitoring Devices Improve Adherence in Patients Failing Second-Line Antiretroviral Therapy? Evidence from a Pilot Study in Johannesburg, South Africa. AIDS Behav (2016) 0.76
Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa. Trop Med Int Health (2016) 0.75
Imputing HIV treatment start dates from routine laboratory data in South Africa: a validation study. BMC Health Serv Res (2017) 0.75
Treatment outcomes of HIV-positive patients on first-line antiretroviral therapy in private versus public HIV clinics in Johannesburg, South Africa. Clin Epidemiol (2016) 0.75
Marked sex differences in all-cause mortality on antiretroviral therapy in low- and middle-income countries: a systematic review and meta-analysis. J Int AIDS Soc (2016) 0.75
Impact of Unplanned Care Interruption on CD4 Response Early After ART Initiation in a Nigerian Cohort. J Int Assoc Provid AIDS Care (2016) 0.75
Brief Report: Does Most Mortality in Patients on ART Occur in Care or After Lost to Follow-Up? Evidence From the Themba Lethu Clinic, South Africa. J Acquir Immune Defic Syndr (2015) 0.75
HIV-associated mortality in the era of antiretroviral therapy scale-up - Nairobi, Kenya, 2015. PLoS One (2017) 0.75
Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med (2007) 19.78
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS (2004) 11.18
Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis (2005) 9.23
Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One (2009) 8.58
A scandal of invisibility: making everyone count by counting everyone. Lancet (2007) 6.89
Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA (2008) 5.68
Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med (2008) 5.17
HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS (2002) 4.56
Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One (2008) 4.20
Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med (2008) 3.56
Sampling-based approaches to improve estimation of mortality among patient dropouts: experience from a large PEPFAR-funded program in Western Kenya. PLoS One (2008) 3.19
Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr (2005) 3.09
When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther (2006) 2.85
Efficacy of antiretroviral therapy in resource-poor settings: are outcomes comparable to those in the developed world? Clin Infect Dis (2005) 1.98
Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol (1997) 1.97
Mortality and causes of death in South Africa, 1997-2003: findings from death notifications. Euro Surveill (2005) 1.64
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One (2009) 4.52
Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA (2008) 3.78
Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health (2010) 3.34
The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health (2008) 3.16
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health (2009) 2.99
The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One (2012) 2.88
Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med (2011) 2.80
Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med (2011) 2.76
Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS (2009) 2.75
Lost opportunities to complete CD4+ lymphocyte testing among patients who tested positive for HIV in South Africa. Bull World Health Organ (2010) 2.68
Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn (2010) 2.47
Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr (2010) 2.46
Rapid point-of-care CD4 testing at mobile HIV testing sites to increase linkage to care: an evaluation of a pilot program in South Africa. J Acquir Immune Defic Syndr (2012) 2.41
Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS (2011) 2.38
Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med (2011) 2.23
Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa. Int J Epidemiol (2012) 2.19
Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. PLoS Med (2012) 2.18
Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the IeDEA Southern Africa collaboration. S Afr Med J (2009) 2.17
Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr (2012) 2.03
No evidence of sexual transmission of Kaposi's sarcoma herpes virus in a heterosexual South African population. AIDS (2008) 1.99
The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS (2010) 1.92
A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis (2006) 1.87
High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr (2010) 1.86
Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health (2009) 1.82
Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr (2012) 1.78
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis (2013) 1.77
Cost to patients of obtaining treatment for HIV/AIDS in South Africa. S Afr Med J (2007) 1.77
Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health care clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr (2013) 1.77
Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa. AIDS Res Treat (2010) 1.75
Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One (2013) 1.71
Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet (2010) 1.69
Rationing antiretroviral therapy for HIV/AIDS in Africa: choices and consequences. PLoS Med (2005) 1.67
Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa. AIDS Res Hum Retroviruses (2013) 1.67
Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr (2008) 1.62
Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One (2010) 1.62
Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J (2012) 1.58
Loss to follow-up before and after delivery among women testing HIV positive during pregnancy in Johannesburg, South Africa. Trop Med Int Health (2013) 1.58
Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health (2012) 1.57
Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS (2009) 1.56
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis (2004) 1.52
Large-scale affordable PanLeucogated CD4+ testing with proactive internal and external quality assessment: in support of the South African national comprehensive care, treatment and management programme for HIV and AIDS. Cytometry B Clin Cytom (2008) 1.50
Hard choices: rationing antiretroviral therapy for HIV/AIDS in Africa. Lancet (2005) 1.45
The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc (2010) 1.45
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis (2006) 1.44
Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment. PLoS One (2010) 1.42
Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr (2011) 1.42
Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis (2003) 1.41
Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir. Trop Med Int Health (2014) 1.38
Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis (2011) 1.33
Characteristics of patients accessing care and treatment for HIV/AIDS at public and nongovernmental sites in South Africa. J Int Assoc Physicians AIDS Care (Chic) (2008) 1.31
The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S Afr Med J (2008) 1.30
Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis (2009) 1.30
Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis (2003) 1.29
Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. Trop Med Int Health (2012) 1.29
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS (2003) 1.29
Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS (2011) 1.28
Transmission of Kaposi sarcoma-associated herpesvirus between mothers and children in a South African population. J Acquir Immune Defic Syndr (2007) 1.22
Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. AIDS (2013) 1.20
Diverse and high prevalence of human papillomavirus associated with a significant high rate of cervical dysplasia in human immunodeficiency virus-infected women in Johannesburg, South Africa. Acta Cytol (2009) 1.20
Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis (2008) 1.17
Implementation of a safer conception service for HIV-affected couples in South Africa. AIDS (2014) 1.17
Kaposi's Sarcoma in HIV-infected patients in South Africa: Multicohort study in the antiretroviral therapy era. Int J Cancer (2014) 1.16
Same-Day CD4 Testing to Improve Uptake of HIV Care and Treatment in South Africa: Point-of-Care Is Not Enough. AIDS Res Treat (2013) 1.14
Pregnancy and virologic response to antiretroviral therapy in South Africa. PLoS One (2011) 1.14
Cost and outcomes of paediatric antiretroviral treatment in South Africa. AIDS (2013) 1.12
Treatment outcomes after 7 years of public-sector HIV treatment. AIDS (2012) 1.11
Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clin Infect Dis (2012) 1.11
The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc (2011) 1.11
Evaluating nurses' implementation of an infant-feeding counseling protocol for HIV-infected mothers: The Ban Study in Lilongwe, Malawi. AIDS Educ Prev (2009) 1.07
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis (2010) 1.07
A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis (2011) 1.07